Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06104488 · ClinicalTrials.gov registry record · Phase 1
A Study of Avutometinib for People With Solid Tumor Cancers
A Phase 1 study of Neuroblastoma and Low Grade Glioma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 2
- Study locations
NCT06104488 is a Phase 1 study of Neuroblastoma and Low Grade Glioma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06104488, a Phase 1 study of Neuroblastoma and Low Grade Glioma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.
Conditions Studied
Interventions
- DRUG Avutometinib
Study Locations (2)
Georgia
- Children's Healthcare of Atlanta (Data Collection Only) - Atlanta
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2029-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06104488
The ClinicalTrials.gov registry entry for NCT06104488 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (90% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Avutometinib is the first listed.
NCT06104488 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT06104488 about?
NCT06104488 is a clinical study titled "A Study of Avutometinib for People With Solid Tumor Cancers". The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.
What is the current status of trial NCT06104488?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2023-10-20. Estimated completion is 2029-10-20.
What conditions does trial NCT06104488 study?
This clinical trial studies the following conditions: Neuroblastoma, Low Grade Glioma, Refractory Cancer, Plexiform Neurofibroma, NF1.
What interventions are being tested in trial NCT06104488?
The interventions under investigation include: Avutometinib (DRUG).
Who is sponsoring clinical trial NCT06104488?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06104488 being conducted?
This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.